Purple Biotech Ltd. (PPBT)

Purple Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	14.49	15.03	10.89	11.25	4.39
Short-Term Investments	0.92	17.08	36.31	46.56	2.01
Cash & Cash Equivalents	15.41	32.11	47.2	57.81	6.4
Cash Growth	-52.01%	-31.96%	-18.35%	803.91%	-4.32%
Receivables	0	0	0	0.5	0
Other Current Assets	0.38	1.14	1.27	0.98	1.91
Total Current Assets	15.79	33.26	48.47	59.28	8.3
Property, Plant & Equipment	0.47	0.68	0.9	0.97	0.24
Long-Term Investments	0	0	0.35	3.07	0
Goodwill and Intangibles	28.04	20.68	20.48	20.48	6.17
Total Long-Term Assets	28.51	21.37	21.73	24.52	6.42
Total Assets	44.3	54.62	70.2	83.8	14.72
Accounts Payable	7	6.86	4.05	2.89	3.35
Current Debt	0.19	0.19	0.2	0.21	0.2
Other Current Liabilities	2.52	0	0	0	0
Total Current Liabilities	9.7	7.06	4.25	3.1	3.55
Long-Term Debt	0.16	0.32	0.55	0.69	0.03
Other Long-Term Liabilities	0.14	0.15	0.29	0.27	0.29
Total Long-Term Liabilities	0.3	0.47	0.84	0.95	0.31
Total Liabilities	10.01	7.52	5.09	4.05	3.86
Total Debt	0.35	0.52	0.75	0.9	0.22
Debt Growth	-31.84%	-31.24%	-16.31%	301.35%	-
Retained Earnings	-137.45	-117.57	-95.91	-77.52	-49.52
Shareholders' Equity	34.21	46.91	64.83	79.39	10.42
Net Cash / Debt	15.06	31.6	46.45	56.91	6.17
Net Cash / Debt Growth	-52.34%	-31.98%	-18.38%	822.07%	-7.66%
Net Cash Per Share	-	-	2.64	4.95	3.19
Working Capital	6.09	26.2	44.22	56.18	4.76
Book Value Per Share	1.72	2.63	36.90	69.03	53.81

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).